Springer - Resistance to Proteasome Inhibitors in Cancer

This academic text from Springer examines the complex landscape of proteasome inhibitor resistance in human cancers. It provides a detailed look at why drugs like bortezomib and carfilzomib encounter challenges in treating conditions such as multiple myeloma. By investigating the molecular mechanisms behind these resistances, the book offers a deep understanding of how cancer cells adapt to targeted therapies. Readers will learn about cutting-edge strategies designed to overcome these barriers. The content covers the development of second generation 20S proteasome inhibitors and the potential of novel combinational therapies. It also explores new targets within the ubiquitin-proteasome pathway, including ubiquitin E3 ligases, deubiquitinases, and 19S proteasomal ATPases. Additional topics include the roles of histone deacetylases, oxidative stress, and proteotoxic stress pathways. The book also addresses pharmacogenomic signature profiling as a method for understanding resistant cancer cells. This resource is a valuable addition for medical professionals and researchers focused on advancing targeted anti-cancer therapeutics.